The historical rank and industry rank for Jacobio Pharmaceuticals Group Co's FCF Margin % or its related term are showing as below:
JBPHF'
s FCF Margin % Range Over the Past 10 Years
Min: -634.22 Med: -213.23 Max: 13.96
Current: -398.74
During the past 8 years, the highest FCF Margin % of Jacobio Pharmaceuticals Group Co was 13.96%. The lowest was -634.22%. And the median was -213.23%.
JBPHF's FCF Margin % is ranked worse than 68.93% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs JBPHF: -398.74
Jacobio Pharmaceuticals Group Co FCF Margin % Related Terms
Jacobio Pharmaceuticals Group Co FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co FCF Margin % Chart
JBPHF vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Jacobio Pharmaceuticals Group Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobio Pharmaceuticals Group Co FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jacobio Pharmaceuticals Group Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Jacobio Pharmaceuticals Group Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobio Pharmaceuticals Group Co (JBPHF) has a FCF Margin % of -876.08% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. According to the industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #661 out of 959 companies in the Biotechnology industry, placing it in the top 68.9%.
Is Jacobio Pharmaceuticals Group Co's FCF Margin % too high?
Jacobio Pharmaceuticals Group Co's current FCF Margin % is -876.08%. Based on the distribution chart, Jacobio Pharmaceuticals Group Co ranks #661 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jacobio Pharmaceuticals Group Co ranks #661 out of 959 companies for FCF Margin %. This places Jacobio Pharmaceuticals Group Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. Jacobio Pharmaceuticals Group Co's current FCF Margin % is -876.08%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current FCF Margin % of -876.08%. The stock's GF Value™ is $0.42, compared to a current price of $0.87 — trading 106.6% above its estimated fair value. The current FCF Margin % is -876.08%. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current FCF Margin % is -876.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued.
The current stock price of $0.87 is trading 106.6% above its estimated GF Value™ of $0.42.
Key valuation signals for JBPHF:
FCF Margin %: -876.08%
GF Value™: $0.42 vs. price of $0.87 (106.6% above fair value)
No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobio Pharmaceuticals Group Co Business Description
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score
Get the complete analysis for JBPHF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JBPHF has been successfully added to your 
